Glaxo's In-Licensing Binge Continues
The message of GSK's recent $270 million dollar licensing deal with Adolor is that, so long as Big Pharma pipelines are suffering and patents keep expiring, late-stage products from small companies can command highly respectable prices. And GSK’s active dealmaking shows that this company, unlike many of its competitors, recognizes that late-stage products still carry enormous risk.
You may also be interested in...
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.